At a glance

What is cerebrolysin?

Cerebrolysin is a preparation of low-molecular-weight peptides and free amino acids produced from pig brain tissue. Cerebrolysin is also known as Cere and FPF-1070. It is not a single peptide but a mixture, and its exact composition is not fully defined. It is approved and used as an injectable in several countries for conditions such as stroke, dementia, and traumatic brain injury, and it is marketed more broadly for cognition. It is not approved in the United States.

How does it work?

Cerebrolysin is proposed to act like the brain's own neurotrophic factors, the signals that support the survival and function of nerve cells. In laboratory and animal models it has shown these effects:

• Neuroprotective¹
• Anti-apoptotic²
• Anti-excitotoxic³

Because the preparation is a complex mixture, its precise active components and mechanism are not fully characterized. This describes the proposed mechanism, separate from whether it improves outcomes in people.

Is it FDA-approved?

No, not in the United States. Cerebrolysin is not approved by the FDA and is not an FDA-recognized compounding substance. It is used clinically in more than 50 countries⁴, including parts of Europe, Russia and the CIS, China, and South Korea, for stroke, dementia, and brain-injury indications.

What does the research show?

It has genuine human trials, and the pooled results are largely unfavorable. The main reviews reached these conclusions:

So despite extensive testing, the human evidence does not establish a clear benefit.

Frequently asked questions

Is Cerebrolysin FDA-approved?

No. As of September 2026, Cerebrolysin is not approved by the FDA for any indication. It is used clinically in more than 50 countries⁸, but no US pharmaceutical channel exists for Cerebrolysin.

Is Cerebrolysin legal in the United States?

Cerebrolysin is not legally marketed for human use in the United States. There is no FDA-approved product and no compounding pathway for this proprietary porcine-derived preparation. Importation for personal use carries legal and safety risk. Access outside of a registered clinical trial is not authorized.

Can a doctor prescribe Cerebrolysin in the US?

No US-licensed physician can prescribe Cerebrolysin within any legal framework, because the compound is neither FDA-approved nor eligible for compounding under US law. Physicians cannot prescribe or dispense it in the United States.

Does Cerebrolysin actually work?

The human evidence does not establish a clear benefit. Manufacturer-funded trials such as CARS reported better arm function⁹ after stroke, and the CAPTAIN trial series reported a small-to-medium benefit¹⁰ after traumatic brain injury. Independent Cochrane reviews, most recently updated in 2023, have found moderate-certainty evidence of no beneficial effect on death in acute ischemic stroke, with a possible increase in non-fatal serious adverse events. The two bodies of evidence measured different outcomes, and the Cochrane authors rated much of the stroke trial evidence at unclear or high risk of bias⁵.

What is the difference between Cerebrolysin and a peptide supplement?

Cerebrolysin is a proprietary injectable pharmaceutical extract manufactured by a single company¹¹ (EVER Neuro Pharma, Austria) and used in clinical settings in countries where it is approved. It is not a dietary supplement. Oral peptide supplements sold over the counter are chemically, regulatorily, and clinically distinct from Cerebrolysin.

What did the Cochrane review find about Cerebrolysin?

The 2023 Cochrane systematic review pooled seven RCTs including 1,773 participants⁵ with acute ischemic stroke (one trial tested a similar agent, Cortexin). It found moderate-certainty evidence of no beneficial effect on all-cause death (RR 0.96, 95% CI 0.65 to 1.41) and a possible increase in non-fatal serious adverse events (RR 2.39, 95% CI 1.10 to 5.23; 3 trials, 1,335 participants). It updates a review first published in 2010 and last updated in 2020.

Why is Cerebrolysin approved in so many countries if the evidence is uncertain?

International regulatory approvals were granted at different points in time and under different evidentiary standards than current FDA requirements. Many approvals predate the 2023 Cochrane findings. Regulatory bodies in different jurisdictions weigh the available evidence differently, particularly for conditions with limited therapeutic options. International approval does not constitute FDA endorsement and does not resolve the methodological concerns independent reviewers have raised.

More for brain & sleep